coming up, another headwind for biogen's alzheimer's drug.hospital systems are refuse to ing to administer it to patients. the stock down 6%. broker, i've . that's great, carl. but we need something better. that's easily adjustable has no penalties or advisory fee. and we can monitor to see that we're on track. like schwab intelligent income. schwab! introducing schwab intelligent income. a simple, modern way to pay yourself from your portfolio. oh, that's cool... i mean, we don't have that. schwab. a modern approach to wealth management. icy hot. ice works fast. heat makes it last. feel the power of contrast therapy, so you can rise from pain. >>> shares of biogen are dropping after the cleveland clinic and mt. sinai say they won't administer its controversial alzheimer's drug biogen shares are down more than 7% and have been sliding throughout the session out to meg tirrell who has the latest >> reporter: both mt. sinai and the cleveland clinic will not administer the drug right now, both seeming to look for potentially more information, mo

any reason to own biogen >> our estimates have been below consensus.ontinue to see more of these headlines pop up and the controversies will not abate we are staying cautious. pairing that with the back drop of the increasing generic competition and the competitive environment in the sma space is a challenging time for us, we are sticking to the sidelines on biogen. >> laura chico of wedbush securities a big and a lot of money on both sides of the biogen story. you say stay away for now. neutral rating laura, thank you >> thanks, brian. >>> on deck, the doctor is in. dr. jon najarian is with us. by the way, the rbi we have been teasing all morning. the industry that we said was dead is now bouncing back. you have to hear this. follow our podcast on all of the available podcasting platforms dow futures up 88. we're positive on the week we're back after this. sofi is a one-stop shop for your finances designed to work better together. save, spend, borrow, invest, and earn cash back rewards, all in one app. that's how you get your money right with sofi. ta

any action here on biogen? >> you know, my colleague was saying this is a lot like olympian whose results are questioned because of the doping, right. and this is one of the kind of things that headlines could be seething this company for a while. so we don't trade it i think guy called it weeks ago. you buy lilly. i think that he had a great call on that. they've obviously done a lot in the alzheimer's space and would you be careful about biogen here if you have to trade it, the low end is about 323 >> yeah, guy, i mean, obviously she's giving a shoutout on the lilly side as well you still have an opinion on that and also biogen. >> no, i appreciate nadine remembering that and we said when it was trading north of 410, this is the opportunity to take profits it is the news you've been waiting for and got it and look for a pullback and you buy it with both hands at 330 and the stock traded 370. but today, you are right about the two hospitals and the unh commentary didn't help either. but biogen management addre

biogen shares down 3% on this. there have been a lot of questions about the drug beyond just the approval process, about the data itself and more recently the price that was set when it was approved in june so, dom, this is a controversy you've seen it go to congress. it's going to continue to brew back over to you >> if you will allow me to follow-up for a second shares are down 3.5% we're seeing a bit of a pickup here can you just kind of set the scene for us yet again because not all of us follow it as closely as you do. what exactly is the controversy around the reason why biogen's and it's approval process has gained so much scrutiny. alzheimer's and everything else has been a huge point of contention for a lot of folks out there in the past. why is it that this particular drug is getting so much more attention because of that regulatory review process? >> yeah. so, a lot of people have alzheimer's disease, 6 million people and no drugs have ever been approved that actually work on its underlying causes. so, b

gut punch because, you know, i do believe this has helped me. >> reporter: while in a statement, biogen said we will cooperate with any inquiry as tonight millions of families facing alzheimer's wait for answers about the drug that once brought so much hope. kristen dahlgren, nbc news >>> two controversial monuments are set to come down this weekend after a years' long legal battle in charlottesville, virginia, the confederate statues of generals robert e. lee and stonewall jackson will both be removed those two statues became a flash point, sparking that deadly white supremacist rally in 2017. >>> up next, a new twist in the billionaire space race >>> richard branson's blastoff on sunday to the edge of space. but in the billionaire space battle, a new twist. here is tom costello >> reporter: down to the wire as richard branson's virgin galactic showcases the final preps for its spaceship. on sunday flying to 50,000 feet before release. >> fire. >> fire. >> reporter: then rocketing to the karman line that marks the edge of space. nasa and the air force say that line is 50 miles high vir

janet woodcock writing she is concerned about cocontacts between representatives from biogen and fda during that review process, including some that may ve occurred outside of the formal correspondence process. >> is one of the worst decisions i can remember >> reporter: dr. aaron kesselheim resigned from the fda advisory committee after the drug's approval last month. >> if there is data that the fda has that we don't know about that might justify aspects of the decision, then we should know that >> reporter: approval of aduhelm was already controversial after evidence of its effectiveness was inconclusive the drug, which costs $56,000 a year was first approved for all approximately six million ericans who suffer from alzheimer's. this week, that was revised to those in n the disease's early stages like p phil gutis, who participated in the drug's trials. >> it is a little bit of a gut punch because, you know, i do believe this has helped me. >> reporter: while in a statement, biogen said we will cooperate with any inquiry as tonight millions of families facing alzheimer's wait for

that's why biogen and fda made the move it doesn't help people who are farther along. >> meg, thank youiggest name have been on a wild ride over the last month, falling significantly from ride, how the meme trade is holding up that's ahead >>> and we have a look at how the dow finished up today, down 260. well off the session lows as you well off the session lows as you can se only from fidelity. ♪♪e that. it started with an idea... and became a new tradition. ♪♪ this is financial security. and lincoln financial solutions will help you get there as you plan, protect and retire. this is lincoln financial. >>> meme stocks being hit hard over the last month, but a few of the key so called reddit trades managed to see some gains amid today's broader selloff kristina partsinevelos here with more >> that's right so many must be playing the meme game because companies like you mentioned, amc, gamestop, blackberry, countered to the market today. we have seen these clocks climb when we see a buy the dip market, especially when crypto tracks lower there would be short seller coverage contributing

biogen said it would corporate, the drug called aduhelm has come under fire from medical experts. tonight a pentagon spokesperson admits there is a deteriorating security situation in afghanistan as the taliban rapidly gains ground. cbs's charlie d'agata is in kabul where they spoke with a top u.s. diplomat about u.s. embassy security. >> reporter: a surprise declaration from the taliban today, the group has now taken control of 85% of afghanistan. the afghan government dismissed the claim but no one disputes'sd territorial ins ar csing shockwaves in the capital and increasing concerns at the u.s. embassy. it's only a few short miles from the u.s. embassy to the airport, but long before the u.s. drawdown, american diplomats have been shuttles back and forth by helicopter, the roads are too risky. the situation has prompted comparisons with the rooftop rescue of persons from saigon in 1975. >> there's going to be no circumstance where you're going to see people being lifted off the roof of an embassy -- >> reporter: yet, the u.s. embassy has been upping its security protocols. >> w

biogen previously said the u.s. in the premarket this morning, the stock is now flat. time for the word on wall street, top investors watching your money. joining me now is stifle chief economist lindsey piezga, tom leiden and mike murphy. thank you for being here. futures are trading higher, the nasdaq is still lower, after yesterday's selloff. i want to point your attention to bond yields. they're stabilizing this morning, the 10 year treasury yield at 1.3%. lindsey, we've been talking about the second half, even though yields are higher this morning there are still worries about slowdown in growth expectations later this year. what are your expectations for growth? have you taken them in a bit and what's your take on what's going on in the bond market? >> it certainly has been a wild ride with yields retreating to a five-month low as of late. really reflecting the latest data that we've seen in the us. it's interesting, because the latest data has been very robust. we're seeing very strong numbers in the u.s. fro

nvidia and biogen ramping it out, biogen facing questions on its new alzheimer's drug, whether regulatorst's the latest news there. nvidia off 9.5. the cruise lines under new covid concerns, norwegian, by the way, has sued the states of florida from prohibiting businesses from -- for prohibiting businesses from requiring proof of vaccinations. all down 12, 13, 15% down for norwegian. >>> all right. gamestop and amc trying to finish another rough week on a high note. maybe not. to how about gamestop? up 1.5%. amc down nearly 3%. and as charlie gasparino pointed out, turning negative here in just the final hour on amc are. the reddit all-stars going all cold in july, as you can see, down for the month. amc off 38 percent. gamestop off, well, nearly 21 percent. however, our countdown closer is still hot on the trend. joining me now, my good friend ryan payne. great to see him, president of payne capital management and host of the payne points of wealth. you're a busy guy, ryan. okay, meme stocks -- it's a big title, a really big business card. meme stocks, you're still not counting these out

miguel in new york miguel >> caller: hey, jim, first-time caller what happened with biogen. you i'm intrigued because the data doesn't look that good. stick with it. it's real spec but stick with it mark in florida. >> caller: this is mark. thanks for all your encouragement, jim. >> i'm trying. what's going on? >> caller: my question about marion technologies san ramon, that ticker symbol gsah. >> well, that is, you know, frankly, that's a very important spac i don't know enough about so i can't comment i've got to do work on that particular spac because i do hear things that goldman is involved i believe with them let's go to peter in illinois. peter. >> caller: hi, this is peter's mom. peter has a question for you. >> okay, sure. no problem >> caller: the chinese auto ev company. i bought it at $34 it went up to 55 but now it crashed to 45 >> young man, listen to me we're done with chinese ipos i want to you sell it. sell half tomorrow and hope it goes up. i love your interest but i am very worried about china and so if i saw you in person i would say, hey, buddy, come on

voted unanimously saying that biogen's new all timers drug does not provide more benefit to patients. >> that supportive care to us. the institute for clinical and economic review met with biogen representatives patients, caregivers and the rolla justice, the panel is studying health benefits and long-term cost effectiveness of the company's new drug. how to help this decision came after 2 major health centers announced they will not carry the drug, which a lot of people say is wildly overpriced as well. the drug marked the first all simers medication to enter the market. nearly 2 decades. it was granted accelerated approval from the fda. and cbs is pulling 2 store-branded sun products from its shelves following the johnson and johnson sunscreen recall the pharmacy chain is removing its cvs health after sun aloe vera and cbs health after son, aloe vera spray from its inventory. you see some of the products in question here. the store says it is pulling those out of an abundance of caution, johnson and johnson's most recent recall involved those 5 sunscreen products including neutrogen

doctor is concerned about contact between representatives from biogen and the fda in the review processedicine okayed against the recommendation of the experts. one resigned after approval. >> if there is data that fda has we don't know about to justify the decision, we should know it. >> several members of congress have launched an investigation. >> barbara lee is lawmakers petitioning to remove marijuana from banned substance list. comes after sha'carri richardson was suspended. alcohol with proven health risks is not. >>> giants took on a new look tonight. fans are not quite sure about it. sports next. >>> giants had a new look tonight as they opened a three-game series against the washington nationals. giants wearing new alternate home jerseys tonight. opinions of the new rags are all over social media. for the game, giants won 5-3. darin ruf with a long home run in the bottom of the fifth to put san francisco ahead. >>> a's headed north to play the rangers after four games in houston but results weren't much different. texas's garcia singled off romo two runs that gave them the lea

a setback for biogen's new alzheimer's drug.ion the fda's approval of this biogen drug amid mixed clinical trial results and a very high price. the fda ordered an independent federal probe to its representative's interactions with biogen. right now the stock is down about two-thirds of 1%. time for the word on wall street, top investors watching your money. joining me is strategic wealth had partners investment strategist, luke lloyd, chief economist lindsey piegza and mike murphy. great to see everybody this morning. thank you so much for being here. lindsey, kicking things off with you. we've got a market that is trading up fraction nailly as we -- fractionally as we wrap up the week, and the first week of earnings season. what do you make of this last week with all of the earnings out as well as the economic data we saw. we've got cpi, the ppi, and we're waiting on retail sales this morning out at 80:00 a.m. -- 8:30 a.m. >> it was a pretty solid week with the exception of the ppi and cpi continuing to move forward. looking ou

biogen standing behind the drug. >>> when we come back here, the sunscreen recall tonight because ofer-causing chemical. 4 my heart doesnpump enoud so my doctor gave me farxiga. it helps my heart do its job better. farxiga helps keep me living life and out of the hospital for heart failure. do not take if allergic to farxiga. symptoms of a serious allergic reaction include rash, swelling, difficulty breathing or swallowing. stop taking and seek medical help right away. tell your doctor right away if you have red color in urine or pain while you urinate, or a genital area infection since a rare but serious genital infection may be life-threatening. do not take farxiga if you have severe kidney problems or are on dialysis. other serious side effects include dehydration, sudden kidney problems genital yeast and bacterial infections in women and men, urinary tract infections, and low blood sugar. stop taking farxiga and call your doctor right away if you have symptoms of ketoacidosis which is serious and may lead to death. more time with her? sounds good to me. ♪far-xi-ga♪ if you can't a

and we'll ask about biogen's sell offon the alzheimer's treatment. >>> later on the show, the ceo of canopy growth joins us. >>> first of all, let's focus on the big stories. mike santoli is tracking the record, and steve liesman has a look at the data you said trfr fridays looked god lately, but what happened? >> there's been a graph stational pull under the service market just more stocks down than up. there's been a problem how many stocks were undergoing profittaking, and really in correction mode, whereas the s&p 500 just about 1% off its highs, but definitely showing we're in a two-week pause take a look to outside the s&p 500, it sells some of the story of the below the surface weakness the vanguard extended mark is everything in the u.s. market. it was a big outperformer, small caps doing great, large cap emerging tech doing great. that's done nothing since february now we have crossed over where we have really, it's the blue chips really holding things up the nasdaq is actually a bit weak today maybe at the violate some technical stuff on the down side moderna shares up a lo

biogen and a potential fda probe. caroline: great moves. thank you very much.f venture capital founders are black. my guest is trying to join that now -- trying to grow that. demo day is the culmination of months where you have been working with entrepreneurs, startups that were initially pitched, then you narrowed it down to 15. >> it's great to be here with you today. it went so well. it is the culmination of five months of our innovation lab. we are offering capital, content, and connection. we have 15 companies present. it was a unique opportunity for them to meet over 800 investors that signed up. to make connections to help them raise money for future rounds and to keep their businesses going. caroline: multicultural founders, female founders, what sort of investors are they across-the-board? >> yes, they are fully across-the-board. we usually seeing media, enterprise, fintech, health care. you really start to see the founders of color and women who have wonderful ideas that are beginning to open up the pipeline. caroline: where did they say they feel the

a real sore one 10-0 ten out of ten on the panel said don't use -- this should not be authorized, biogen and the fda approved it >> yeah. >> so how have thet not approved these vaccines because if you had approval you could order. if you were a major company, you could say, okay, listen. everyone has to take this. >> and now the government's going to look bether medicare will cover and that decision will take about nine moss. >> very questionable >> over in london, talking about having a vaccine, considered a violation of -- the magna carter, cribbed a lot of stuff from, david. >> it's in the uk. report out today disneyland paris will require a sanitary pass, that he call it, starting next week. >> jpecs starting to makegood moves. >> stock went up and why you're saying that? >> the facts are changing in a more positive way. good set of facts. >> actually a nice breakout. >> it has. talking more of -- >> didn't you get the, 6:15, get the espn pricing piece 6:15 p.m. >> i think it's morgan stanley this morning, a bullish note subpoena that jessica? >> yeah. and i do like the fact -- >> ta

biogen calling the moves d disappointing. >> there was so much hope for society, for this kind of drug putting that aside for a moment, what do you do with the stock? >> well, the stock even after dh move is up 33% on the year traded 18 times. it's not exactly cheap here's the thing, i'm surprised it's down so much today, on july 8th, the fda did walk back the original approval and gave it a more narrow label. so this was on july 8th. so you knew there was some uneasiness from the fda, from the company. and from obviously hospitals so the problem is, sarah, the numbers went up 30% -- earnings numbers went up 30% between 22 and 25 just from this drug alone. some people thought this could be in a bull case by 2032, a $28 billion drug, that actually compares to humera and keytruda. the expectations were enormous i get the pull back but i feel like we were prepped for this a little bit, let it settle down if it comes in more they have a great pipeline, management team you may want to look at it >> shares of gm are lower after issuing a warner to some chevy bolt owners. >> this has to do wi

alzheimer's a key focus for many >> especially with everything going on with biogen >>> to tesla, elonwill be opening to other evs later this year by doing so he's helping the competition and giving up something that gave tesla an edge shares of ev stocks are higher on the news today. nio is up nearly 6%. auto and tech reporter for "the wall street journal" tim higgins alongside our very own phil lebeau phil, let's start with the details of this announcement do we understand this properly starting late they are year you don't need one of the other ev networks can you drive up whatever it is and use tesla's charging network. >> theoretically we have no details other than that this was sent out by elon muss nk a tweet yes, the supercharger network will be open to other evs late they are year. we don't know exact timing, what the pricing will be for other evs charging at supercharger sites. that remains to be seen. they're giving up one of the key advantages they have a great footprint. they have great locations not only here in the u.s. but around the world and if you are another ev owne

cleveland clinic says that individual physicians can prescribe the $56,000 a year dug from bio again biogen receive it. mount sinai health system in new york city also decided not to administer the drug. >>> and johnson & johnson advising customers to throw away any bottles of aveeno. there was a cancer causing ingredient found in the product. "early start" continues right now. >>> good morning. this is thursday, and it is "early start." i'm christine romans. >> and i'm polo sandoval. >> and an explosive new book documents the first time in modern u.s. history the nation's top military officer prepared for a showdown with the president. why? because the chairman of the joint chiefs feared a coup attempt by then president trump after he lost the november election. "washington post" reporters write that milley and other top officials informally planned strategies for stopping trump. and they even thought about resigning. one by one rather than carrying out orders they considered illegal, dangerous or ill advised. the authors explain that general milley was concerned about personnel moves that

biogen, the alzheimer's drug generating 2 million in revenue.ecast, shares up 1.5% and las vegas sands after reporting a wider-than-expected loss however, the company said it's still confident about a rebound in travel and tourism you can see the shares down almost 5% this morning. >> another name to watch, southwest airlines under pressure after a wider-than-expected loss ceo gary kelly joined us in the last hour to discuss the quarter. >> these are very good results our revenues almost doubled from the first quarter levels and the bookings for the third quarter look really strong relatively. we were profitable in the month of june and we've got a good shot at profitability for the third quarter as a whole so there is no affect on our demand right now from the delta variant, and, hopefully, that will continue to be the case >> that's gary kelly, of course, southwest. no impact from delta, morgan and everybody it seems, all the ceos in the airlines fspace are optimistic about at least where look y leisure is where you have been vaccinated or not

down about 1% technology is the worst performing sector of the day >> time now power movers first up biogenoday the cleveland clinic and mt. sinai announced they won't administer the drug to patients. the fda chief telling a reporter to move on after being asked about its approval reporters love to be told to move on, by the way. the stock down 16% >> never a way to get people off the story when you handle it like that. shares of just eat, the parent company of grub hub, delivering order growth of 47%. but analysts at citi say they continue to struggle with profitability. >> and finally, raymond james upgrading delta to strong buy from market perform. the analyst saying it is too hard for market valuation. >>> now during the pandemic many people fled south making florida real estate and miami very hot in the wake of the surfside condo collapse some are worried about other buildings in the area diana olick joins us live with more diana? >> reporter: kelly, miami has long been a tale of two condo markets, those built before the year 2000 when strict new building codes from hurricane andrew we

now the biogen drug will be limited to patients with mild cognitive impairment.opeannion cognitive -- michael avenatti previously represented stormy daniels in her fight with president trump. still to come, how the surfside collapse raises concerns about future investments in other buildings. texas republicans continue their push for restricted voting laws. boomers face complaints about the world they createdplus much more. >> this is the pbs newshour from weta studios in washington, and from the west, from the walter kwok right school of journalism at arizona state university. judy: now the staggering death toll from covid-19. as we mark more than 4 million dead around the world, the actual number will likely never be known. and as the u.s. and other wealthy nations with relatively highaccination rates begin emerging from the pandemic, the disease then variants are accelerating in other parts of the world, killing more quickly than ever. nick schifrin begins our coverage. nick: has south africa walks through the valley of the shadow of death there iplenty of fea

. >> the drug maker biogen expects use should be targeted to a fraction of patients with alzheimer's,ere the drug was tested, about 1 to 2 million patients the company points out the drug was approved based on its ability to clear plaque build ups in the brain associated with alzheimer's, and says it's working to complete a confirm toir trial proving its benefits in memory. and that it's open to working with the government to ensure it doesn't overwhelm medicare, and it's committed to not raise the price for four years as for linda and ed, they don't yet have to pay for the drug since eds of involved in the trial, but when they do, even though they acknowledge the drug is not a cure, they say they don't mind the price if it can bring them hope for a little more time together. >> when i see that he's -- >> she's happy >> when i see that he's there with me, and enjoying the moment like i am, it's huge >> now, the drug itself isn't the only cost. patients also need tests to make sure the drug is right for them, and mri's while they're on it to monitor the safe it's a lot for the system t

now, the biogen drug will be limited to patients with mild cognitive impairment or mild dementia. the european union has fined german automakers $1 billion for blocking emissions controls that might help address climate change. the companies are bmw and volkswagen, plus, vw's audi and porsche divisions. e.u. investigators say they kept improved pollution technology off the market. california lawyer michael avenatti, who once sued president trump, was sentenced today to 30 months in prison. he had tried to extort millions of dollars from nike. avenatti previously represented porn star stormy daniels in her legal fight with mr. trump. and, on wall street, stocks retreated after jobless claims rose slightly and investors turned to bonds over stocks. the dow jones industrial average lost nearly 260 points to close below 34,422. the nasdaq fell 105 points. the s&p 500 slipped 37. still to come on the newshour: how the surfside collapse raises concerns about future investments in other buildings. texas republicans continue their push for restrictive new voting laws. boomers respond to m

. >>> final trade time, guys >> biogen. >> karen >> going around the globe, imdy, ndi shares. >> it looksfizer breaking out above this range it's been in for two months. >> thank you for watching "fast money" i'll see you in 12 hours on "squawk box". mad money" with jim cramer starts right now >>> my mission is simple -- to make you money i'm here to level the playing field for all investors. there's always a bull market somewhere. and i promise to help you find it "mad money" starts now hey, i'm cramer. welcome to "mad money. welcome to cramerica other people want to make friends. i'm just trying to make you a little money my job isn't just to entertain but to educate and teach you so call me at 1-800-743-cnbc. or tweet me @jimcramer. may i kindly and politely ask the politicians around the world to c

instructions for prescribing a controversial and expensive alzheimer's drug that could limit its use the biogen or mild alzheimer's and not all stages of the disease as was said when the drug was first approved. >>> get ready for more bad weather this year. researchers at colorado state university have raised the number of named storms they expect this hurricane season to 20 from17. >>> and on the news tonight, another heat wave taking aim at the west coast california towns running out of water. we'll get a live report on how residents are getting by that's tonight at 7:00 >>> and in nebraska, ted turner is donating an $80,000 acre ranch to a nonprofit agriculture research institute and he says he'll keep paying taxes on the land turner is the largest land owner in the state and officials had worried his expected land donations would slash tax revenues back to you. >> rahel, thank you. >>> coming up, we're continuing to watch the rebound in some areas of the market. check out this stock like an action movie amc hit a low below $39 a share right out of the gate this morning. trading at almost 49

acting commissioner said an independent review should consider interactions between the agency and biogenthe company that makes the drug. it is the first medication cleared by the fda to slow cognitive decline in alzheimer's, patients. it was approved last month despite an earlier vote against it by the fda's advisory committee. winter time coming cold now hitting children in summertime. bathily doctors across the nation. pediatricians say many infants have been hospitalized with coughs and difficulty breathing. they are said to be suffering from a respiratory virus, which is a common cause of cold like symptoms. but which can be serious for infants and for the elderly. some experts believe that the recent surge in cases could be partly due to more testing because of people's fears over covid across the country. some hospitals are being overwhelmed by the delta variant of the coronavirus, particularly in the midwest. >> many areas are seeing a sharp rise in covid cases, a story we've heard before that rise coincides with low vaccination rates has time to govern reports many health care wo

average is this a major step toward a universal basic income >>> and controversy growing around biogen'ser's drug just days after the center for medicare and medicaid began its review, two major hospital systems are saying they won't use it does it have a future? plus, quitting crypto, souring on oat milk, and don't charge in

up, the agency would like the office of the inspector general to review the approval process for biogen'sheimer's drug, specifically how interacted with the company. that's down by more than 3%. the cdc and fda say people don't need a booster just yesterday. >> but great news either way. >> pfizer does have good news, it showed if you get a third dose of its original vaccine, you can boost antibodies up to what they called encouraging levels the questions between the fda, cdc and pfizer come down to pfizer saying they are more convinced with new data that we will need boosters 6 to 12 months after the original vaccination, basing it on real-world data. even though it remains high as we've been talking about that's why they're saying this third dose may be needed six months to a year after the first vaccination. we caught with the head of israel's biggest hmo about how they're thinking about booster shots in that country. >> we should give them the third shot of covid for the most aggressive patients. for the general population, i think it's too earl. probably yes, not in the next month, m

biogen share sank almost 7% on thursday to the lowest in more than a month after two major hospital systems a group of health insurers said no to administering is controversial alzheimer's medicine. the u.s. food and drug administration approved a drug on june 7, even after an advisory panel recommended against it. a pickup in demand in the cruise industry. the ceo says 2022 bookings are on the rise and pricing is stronger than 2019. >> my experience right now is the economy is strong and there is a lot of pent-up demand. people are anxious to travel and to enjoy things again. for quite some time that been on lockdown or near lockdown. so there is a lot of excitement and interest. shery: softbank's vision fun is investing $1.7 million in south korean travel apps ahead of an ipo that is in planning. sources say the deal boost his value to more in business, it's never just another day. it's the big sale, or the big presentation. the day where everything goes right. or the one where nothing does. with comcast business you get the network that can deliver gig speeds to the most businesses and a

treatment so far is something called tofersen from biogen.to slow the progression for a rare form >> i work every day. >> reporter: chris snow got access to tofersen through a clinical trial. it is given via a spinal injection every four weeks. >> i don't necessarily feel like myself or look like myself, but i act like myself. >> reporter: it not only targets a particularly aggressive form of a.l.s., but it is just that that took the lives of chris' father, two uncles, and his 28-year-old cousin. at the time he started on the new drug, he was given less than two years to live. that was almost two years ago. >> he should be dead, that's the simplest way to put it. he looks pretty good for a dead person. >> reporter: he got back on the ice and plays hockey. he is the assistant general manager for the calgary flames. >> the quality of life >> reporter: tofersens is has completely halted a.l.s -- chris has still seen changes in his facial muscles, he can't really smile and he has trouble speaking and swallowing, but many of his other symptoms hav

biogen is up about a quarter percent in the premarket.art to get more expensive. starting august 13th disney will raise the monthly price by a dollar, as they ink new deals with the nhl, nfl and wimbledon. they will not change the price of the bundle. those are some of your headlines from here. we are standing by with jp morgan earnings. maria: i think it could be a market mover. austin miller, the u.s. general leading the war in afghanistan, stepped down yesterday in a symbolic end to the war. on sunday morning futures i spoke with former secretary of state mike pompeo about what happens now in afghanistan as we understand that china is waiting in the wings to go in. watch. >> the civilians are charging and president trump had the same kind of resistance from the military as well to reduce our footprint in afghanistan, ultimately his decision as the leader to begin this march towards having fewer and fewer troops there in afghanistan. it's all about how you execute it. your point about the chinese is well taken. frankly, we provided secu

it was first developed with biogen and controversially approved by the fda. let's move onto korea. bank of korea seeing its monthly money supply figures at noon local time. too many rate hikes are priced into government bonds at this time. swap markets are considering three increases over the next 12 months, more than bearings korea. the covid delta variant is spreading rapidly in seoul, haiti. haidi: -- haidi. haidi: the fda is adding that warning about the risk of a rare immune disorder to johnson & johnson's covid vaccine. the u.s. regulator said the data was insufficient to say definitively if that had caused the illness. as with any new drugs coming onto the market, we expect to see these adverse events. what do we know about this affecting some people back at the j&j shot? -- some people that get the j&j shot? >> of that, 95 were hospitalizations, one was a death. this is an incredible he condition and the u.s. food and drug administration revived the fact sheet for j&j to warn vaccine providers and doctors of that disorder within 42 days of being administered dose. we know t

. >> we're talking about the biogen drug for alzheimer's. >> how many people have to take the vaccineefore they say, you know what? it's not emergency use >> the nfl, how did you get to the nfl. it doesn't trade publicly, jim. >> i want to go to the nfl i want to go to football games. >> you do? oh, that's what you're talking about. >> i'm worried about games. >> you're going to be able to go to games they're outdoors. >> can i go to the tepper versus eagles game? >> am i allowed to take tickets from tepper? he's private i'll pay face value. >> let's take a look at shares i want to talk about didi for a second if you are -- by the way, there are a number of hedge funds that have significant china businesses and/or private equity funds. you do have to wonder, and some of them stepped up big and own a lot of didi. mine, 14 bucks, that was, what a week ago where it was priced and then it went up from there. >> xi decides to host. >> its market value now is as high as 75 bil or more it's now $53 billion. >> just do wonder in six months is a lot of this past or is this the new world? >> i

why the fda is doing what it's doing, why they went against ten people out of ten voted against the biogen drug, they still approved it. >> they now have reduced the label, they reduced the patient population it's for. >> to quote the late roger ailes when i first decided to disagree with him you are really off the reservation. >> did he say that to you. >> that was one of the more frightening periods of my life when i worked for roger. >> i do want to come back to something i've been following for a year and a half, or close to it. a drug we've talked about a lot. it's the merck drug. it's an antiviral. they're in the midst of phase three study around the world enrolling as many as 1,450 patients who know they have covid but it's early you give them the oral antiviral and see what happens >> tamiflu. >> exactly in india, hetero, which is a company that is a vertically integrated pharmaceutical company in india, they actually had a voluntary license for had this. >> they do. >> and they've given us a look at kind of an interim study. 741 patients is what we're talking about. they want to e

on debt, we'll hear from the likes of intel, alaska air, american airlines, snap, at&t, southwest, biogenink a greater percentage are beating than even normal, and just the year-over-year numbers are mind boggling, 75%, you know, earnings growth over a year ago. the issue is you go back two year-t years you're probably looking at 15% s&p profits above 2019 comps. still healthy. >> really strong, i was going to say this week and for the most part responding to those earnings in a way that perhaps didn't with banks but might because it came off the monday's gut check. >> that might be the case, and especially the economically sensitive stuff that got beat up netflix really heavy volume on that pullback on netflix there's push pull as there always is. definitely, poor guidance and a reassessment of what you want to pay for that level of growth. >> i think if you are a ceo or you're an investor listening to that c. fauci interview, i think you have to be a little encouraged at least. you know, we pressed him a bunch of times on these breakthrough cases and he really did not -- said that the v

seventy-five-dollar credit when you post your first job at indeed.com/promo >>> another setback for biogen'sheimer's drug three hospitals will not administer it. cleveland clinic and mt. sinai and providence will not carry the drug the cleveland clinic says doctors can describe it, but administered from the outside facility this follows the review of the safety and efficacy. some health insurers are restricting access to the therapy. a spokesperson for blue cross blue shield of north carolina cited the same in the decision not to cover the drug. that is the bigger question. expensive drug if you have hospitals saying they won't administer it, you will have insurance companies saying it is safety and ef efficacy >> depressing. hope springs eternal with something with the aging population it is so urgent we find something that works >> it has been almost 20 years since there has been another drug or treatment approved >> i think this is one of those from the name of it that ends with a monocolonial antibody we don't know if it is plaque which is the result. it is not proved definitively. >> yo

doctor woodcock, some of the fda's reports on the biogen's new alzheimer's drug. i think it's very concerning, last week there was an extra panel convened by the institute for clinical and review that concluded it wasn't efficacious. it didn't provide benefits to patients with alzheimer's and certainly wasn't worth the price tag. i know i saw a couple of research reading my briefs from my orremarks to staff that it could have been handled differently. how specifically differently? >> a lot of the confusion is in some of the controversies as to what you said. this is an accelerated approval u. that means it was approved on a surrogate endpoints that we believe was reasonably likely to predict a clinical benefit. so the conclusion you just referred to is not surprising . we can say it's definitively shown benefits. congress has urged us to use the accelerated approval pathway for life-threatening diseases that don't have any effective therapy . alzheimer's is one. i think part of the issue was it was brought to an advisory committee and proposed for traditional appr

have seen major controversy just over the last couple weeks over all timers drug manufactured by biogenlimited evidence for efficacy coming at the list price is well over $50,000 per patient, per year. there is a reason there is outrage. there are americans who can't afford it and are dying because they can't afford it. in some cases, the policy is more complex than a drug company charging a lot of money. like landscape with pharmacy benefit managers and insurance plans. we see a lot of these discussions the last couple of years about how to fix the problem, but not much action. house speaker nancy pelosi really wants to pass a bill they call to lower drug prices now act. cummings, who was skeptical of these pharmaceutical industry arguments. we will see what happens on that front. it is not clear they have the votes in the house, especially in the senate. remind me of the other question? host: we are running short on time, so let me get to loretta on twitter. is it true that the pharma companies got ppp loans? if so, how much, and doesn't this turn into a kickback scandal, if true? gue